Fundación MEDINA Announces a New Stage of Scientific Expansion to Model Human Diseases for Drug Discovery
Fundación MEDINA is entering a new phase of scientific growth with the launch of an advanced human disease cell models platform, strengthening its capabilities in early-stage drug discovery and translational research.
As an international benchmark in the discovery of new drugs derived from natural products, Fundación MEDINA has long contributed to the generation of high-impact knowledge and advancement of biomedicine through research, innovation, and strategic collaboration. In 2026, the Foundation embarks on a new chapter of growth by expanding its scientific portfolio into key areas of modern biomedical research. The Disease Modelling and Drug Discovery Platform will allow for more precise study of pathological mechanisms and accelerate the identification of new therapeutic targets for diseases like cancer and neurodegenerative disorders. The advanced cells models are compatible with high content screening, and include unique retinal disease models for macular degeneration and diabetic retinopathy. These state-of-the-art systems will allow MEDINA and its partners to work with physiologically relevant models that improve the prediction of therapeutic efficacy at early stages of development. With this expansion, MEDINA positions itself as a comprehensive hub for early drug discovery and development, combining its long-standing leadership in natural products discovery with cutting-edge cellular and molecular biology technologies. “We continue to innovate with our sights set on the future. Our expansion into advanced disease models reinforces our mission: to generate excellent science that translates into real solutions for human health,” MEDINA’s management highlights. The Foundation will continue strengthening collaborations with public institutions, academic centers, and biotechnology and pharmaceutical companies, reaffirming its commitment to innovative, competitive, and socially impactful research.